Traws Positive Topline Phase 1 Results for COVID Therapy Candidate

 Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir

Phase 2a study expected to begin in H1 2025 in patients with COVID

Improving COVID care is an ongoing need, with approximately 50,000 US deaths in 2023

https://www.globenewswire.com/news-release/2024/09/30/2955095/0/en/Traws-Pharma-Announces-Positive-Topline-Phase-1-Results-for-COVID-Candidate-Ratutrelvir-an-Oral-Mpro-Inhibitor.html